Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis (original) (raw)

• Original Article
• Published: 18 May 2000
• Anne-Cécile Hellin1,
• Chantal Lechanteur1,
• Frédéric Princen1,
• Miguel Lopez1,
• Georges Fillet1,
• Jacques Gielen1,
• Marie-Paule Merville1 &
• …
• Vincent Bours1

Cancer Gene Therapy volume 7, pages 20–26 (2000)Cite this article

• 524 Accesses
• 28 Citations
• 6 Altmetric
• Metrics details

Abstract

Gene therapy is a novel therapeutic approach that might soon improve the prognosis of some cancers. We investigated the feasibility of cytosine deaminase (CD) suicide gene therapy in a model of peritoneal carcinomatosis. DHD/K12 colorectal adenocarcinoma cells transfected in vitro with the CD gene were highly sensitive to 5-fluorocytosine (5-FC), and a bystander effect could also be observed. Treating CD+ cells with 5-FC resulted in apoptosis as detected by terminal deoxynucleotidyltransferase-mediated deoxyuridine triphosphate nick-end labeling. In vitro, several human cell lines derived from ovarian or colorectal carcinomas, as well as the rat glioblastoma 9 L cell line, responded to CD/5-FC and showed a very strong bystander effect. 5-FC treatment of peritoneal carcinomatosis generated in syngeneic BDIX rats by CD-expressing DHD/K12 cells led to a complete and prolonged response and to prolonged survival. Our study thus demonstrated the efficacy of CD suicide gene therapy for the treatment of peritoneal carcinomatosis.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 12 print issues and online access

$259.00 per year

only $21.58 per issue

Buy this article

• Purchase on SpringerLink
• Instant access to full article PDF

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

• Log in
• Learn about institutional subscriptions
• Read our FAQs
• Contact customer support

Similar content being viewed by others

Author information

Authors and Affiliations

1. Laboratory of Medical Chemistry/Medical Oncology, University of Liège, Liège, Belgium
   Mohamed Bentires-Alj, Anne-Cécile Hellin, Chantal Lechanteur, Frédéric Princen, Miguel Lopez, Georges Fillet, Jacques Gielen, Marie-Paule Merville & Vincent Bours

Authors

1. Mohamed Bentires-Alj
   You can also search for this author inPubMed Google Scholar
2. Anne-Cécile Hellin
   You can also search for this author inPubMed Google Scholar
3. Chantal Lechanteur
   You can also search for this author inPubMed Google Scholar
4. Frédéric Princen
   You can also search for this author inPubMed Google Scholar
5. Miguel Lopez
   You can also search for this author inPubMed Google Scholar
6. Georges Fillet
   You can also search for this author inPubMed Google Scholar
7. Jacques Gielen
   You can also search for this author inPubMed Google Scholar
8. Marie-Paule Merville
   You can also search for this author inPubMed Google Scholar
9. Vincent Bours
   You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence toVincent Bours.

Rights and permissions

About this article

Cite this article

Bentires-Alj, M., Hellin, AC., Lechanteur, C. et al. Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis.Cancer Gene Ther 7, 20–26 (2000). https://doi.org/10.1038/sj.cgt.7700093

Download citation

• Received: 11 September 1998
• Accepted: 27 February 1999
• Published: 18 May 2000
• Issue Date: 01 January 2000
• DOI: https://doi.org/10.1038/sj.cgt.7700093

Keywords

This article is cited by